Company news

Vortex Energy Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

September 25, 2024

Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for People With Cystic Fibrosis Aged 2 Years and Older With Certain Rare Mutations

July 15, 2024

Vertex and TreeFrog Therapeutics announce licensing agreement and collaboration to optimize production of Vertex's cell therapies for type 1 diabetes

April 23, 2024

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older

November 29, 2023

Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With At Least One F508del Mutation

October 17, 2023

Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation

April 20, 2022

Health Canada Grants Marketing Authorization for KALYDECO® (ivacaftor) for Patients With Cystic Fibrosis Between the Ages of 4 Months and 18 Years With the R117H Mutation in the CFTR Gene

March 25, 2022

Vertex's Supplement to a New Drug Submission for KALYDECO® (ivacaftor) for Patients with Cystic Fibrosis Between the Ages of 4 Months and 18 Years with the R117H Mutation in the CFTR Gene Accepted for Priority Review by Health Canada

September 22, 2021

Health Canada Grants Marketing Authorization for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age

August 25, 2021

Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation

June 18, 2021

Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada

December 28, 2020

The Vertex Foundation Announces Donation to Food Banks Canada to Help With COVID-19 Response

April 24, 2020

CombiMatrix and Vertex Pharmaceuticals Make Gains

March 30, 2017

Blog Coverage Cara Therapeutics Reported Positive Top-line Results

March 29, 2017

Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Exelixis and Vertex Pharmaceuticals

January 27, 2017

Blog Coverage Celgene Acquires Delinia; Set to Expand Inflammation and Immunology Portfolio

January 27, 2017

INCIVEK(tm) (telaprevir) Now Funded for People With Hepatitis C in Quebec and Saskatchewan

April 24, 2012

Janssen Pharmaceutica Announces Collaboration with Vertex Pharmaceuticals to Develop and Commercialize VX-950 for Treatment of Hepatitis C

June 30, 2006

Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV

June 30, 2006

Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C

June 30, 2006

Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients

May 22, 2006

GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV

May 16, 2006

Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients

April 29, 2006

New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Protease Inhibitor VX-950

April 26, 2006

Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF

March 23, 2006

VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon

January 9, 2006

GSK and Vertex Pharmaceuticals Announce Presentation of Data Supporting Development of Investigational HIV Protease Inhibitor Brecanavir

December 16, 2005

GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain

December 13, 2005

FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950

December 8, 2005

AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor

November 11, 2005

New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track

October 3, 2005

← Newer news releases

Decks

The 5 newest of 9 decks. Every deck is listed under its year.